There has been a significant buzz around
Regeneron Pharmaceuticals, Inc. (REGN). The company is preparing for an
$83M charge, influencing multiple stakeholders' decisions. Many entities have increased, sold, or bought new positions in REGN. Notable share transactions include
Arnhold LLC,
Allspring Global Investments Holdings LLC, and
Catawba River Capital. While the company's stock fell in Q2, it demonstrated a rebounding potential after a 43% drop with promising cash flow prospects for 2025. Despite various fluctuations, the stock retains a consensus rating of "Moderate Buy" from analysts. It's noteworthy that the company reported positive results from several
Late-Stage Trials and the successful phase 3
Garetosmab trial for a rare disease. REGN recently also gained FDA approval for
Evkeeza to treat HoFH in children aged 1 to less than 5 and Linvoseltamab for Multiple Myeloma. However, a 27.79% upside is beckoning investors amidst biotechnology innovations. Despite a pricing dip, the analysts from
BMO Capital and
Canaccord maintain a 'Buy' rating. Highlighting the
strong R&D pipeline, analysts foresee growth catalysts incoming. The company also holds a strong market position with a potential to shape the Nasdaq Future.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 11 Jun 2025 07:00:00 GMT to Sat, 18 Oct 2025 11:33:17 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -4
